The Francis Crick Institute
cancers-14-04818.pdf (1.14 MB)

Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): Design of a pragmatic, prospective randomised controlled trial.

Download (1.14 MB)
journal contribution
posted on 2022-10-17, 13:26 authored by Richard D Neal, Peter Johnson, Christina A Clarke, Stephanie A Hamilton, Nan Zhang, Harpal Kumar, Charles Swanton, Peter Sasieni
We report the design of the NHS-Galleri trial (ISRCTN91431511), aiming to establish whether a multi-cancer early detection (MCED) test that screens asymptomatic individuals for cancer can reduce late-stage cancer incidence. This randomised controlled trial has invited approximately 1.5 million persons and enrolled over 140,000 from the general population of England (50-77 years; ≥3 years without cancer diagnosis or treatment; not undergoing investigation for suspected cancer). Blood is being collected at up to three annual visits. Following baseline blood collection, participants are randomised 1:1 to the intervention (blood tested by MCED test) or control (blood stored) arm. Only participants in the intervention arm with a cancer signal detected have results returned and are referred for urgent investigations and potential treatment. Remaining participants in both arms stay blinded and return for their next visit. Participants are encouraged to continue other NHS cancer screening programmes and seek help for new or unusual symptoms. The primary objective is to demonstrate a statistically significant reduction in the incidence rate of stage III and IV cancers diagnosed in the intervention versus control arm 3-4 years after randomisation. NHS-Galleri will help determine the clinical utility of population screening with an MCED test.


Crick (Grant ID: 10169, Grant title: Swanton FC001169)